إپراتروپيوم بروميد/سالبوتامول
| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| البيانات السريرية | |
| الأسماء التجارية | Combivent, DuoNeb, Breva, others |
| AHFS/Drugs.com | FDA Professional Drug Information |
| فئة السلامة أثناء الحمل |
|
| مسارات الدواء | Inhalation |
| رمز ATC | |
| الحالة القانونية | |
| الحالة القانونية | |
| المعرفات | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.040.779  |
| (verify) | |
إپراتروپيوم/سالبوتامول، يُباع تحت الاسم التجاري كومبيڤنت Combivent، هو combination medication used to treat chronic obstructive pulmonary disease (COPD).[2][3] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[2] It is taken by inhalation.[4]
Common side effects include sore throat, muscle cramps, and nausea.[2] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[2] Safety in pregnancy is unclear.[1] Each medication typically decreases bronchospasm and does so via different mechanisms.[2]
The combination was approved for medical use in the United States in 1996.[4] It is available as a generic medication.[3] Sixty doses in the United Kingdom costs the NHS about 18 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$9.50.[5] In 2016 it was the 166th most prescribed medication in the United States with more than 3 million prescriptions.[6]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
المجتمع والثقافة
Since Combivent contains a chlorofluorocarbon based propellant, it is being phased out in European Union countries. Chloroflourocarbons (CFC) are attributed to depletion of the ozone layer.
المصادر
- ^ أ ب "Albuterol / ipratropium Use During Pregnancy". Drugs.com (in الإنجليزية). Retrieved 19 April 2019.
- ^ أ ب ت ث ج "DailyMed - ipratropium bromide and albuterol sulfate inhalant". dailymed.nlm.nih.gov. Retrieved 18 April 2019.
- ^ أ ب ت British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
- ^ أ ب "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com (in الإنجليزية). Retrieved 18 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in الإنجليزية). Retrieved 3 March 2019.
- ^ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
وصلات خارجية
- DailyMed
- Consumer Medication Information from PubMed
- National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
- Template:drugs.com link with non-standard subpage
- ECHA InfoCard ID from Wikidata
- Pages using infobox drug with unknown parameters
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs that are a combination of chemicals
- Beta-adrenergic agonists
- Bronchodilators
- أدوية مركبة
- ضادات مسكارينية
- RTT